Luteolin has depicted increased expression of MiR-26a, which is a regulator of EZH2, and at the same time, it has inhibited EZH2 and H3K27me3, leading to self-programmed death and cycle arrest and apoptosis in prostate cancer cells [45]. The gene discussed is EZH2; the disease is prostate carcinoma.